Articles By Rob Wright

  1. Eli Lilly Research Lab Tour Reveals More Than Meets The Eye 11/1/2013

    Lilly Research laboratories (LRL) opened doors to a select group of media for a rare behind-the-scenes tour of three new innovation labs.

  2. How To Take Charge Of Your Public-Private Partnerships 10/31/2013

    The process of creating a public-private partnership (P3) can be very challenging not only due to the size of the organizations involved (NIH), but the navigation of academic and government-institution policies and procedures for brokering a partnership can be a labyrinth.

  3. From Obscurity To Innovation Engine – The Evolution Of Specialty Pharma 10/31/2013

    By 2018, it is estimated specialty drug spend will surpass traditional drug spend, and in three years market research project 7 of the top 10 bestselling drugs will be specialty drugs. With such as staggering growth how will insurance companies be able to afford to pay for such lifesaving treatments.

  4. Life Science Connect Chief Editors Get Rare Behind Scenes Tour Of Lilly Research Labs 10/8/2013

    Life Science Leader magazine’s chief editor Rob Wright, and Outsourced Pharma and Clinical Leader chief editor Ed Miseta (part of the Life Science Connect group of publications), were recently granted a rare behind the scenes tour of three of Eli Lilly (NYSE: LLY) Research Laboratories (LRL) at the company’s global corporate headquarter in Indianapolis on October 2, 2013.

  5. Operational Excellence — The Solution To Rising Recalls 10/4/2013

    According to Frost & Sullivan’s global pharmaceutical contract manufacturing market research, large pharmaceutical companies increasingly consider outsourcing manufacturing to CMOs because of the uncomplicated, timely, and cost-effective services these companies provide. And while the debate rages as to how big the market will grow over the next three to five years, one thing is certain — life sciences companies don’t select a CMO in the hopes of increasing the number of products they can have recalled.

  6. The Significance Of Recognizing Excellence 10/4/2013

    Welcome to Life Science Leader’s 3rd annual CMO Leadership Awards special supplement — recognizing excellence in pharmaceutical and biologic contract manufacturing. Unlike many other industry awards (e.g. Emmys, Oscars, Grammys), The CMO Leadership Awards are not a popularity contest nor are they determined by our writers and editors via a secret ballot (e.g. Motor Trend Car of the Year).

  7. Does Your Pharma CMO Deliver On Its Promises After Being Acquired? 10/1/2013

    I first met Mark Bamforth, the president and CEO of Gallus BioPharmaceuticals, at a conference shortly after he had acquired/founded his CMO in St. Louis. The company was so new many of the employees at the event didn’t even have business cards.

  8. Private Or Public? Not Really Even A Question In Life Sciences? 8/29/2013

    When launching a start-up in the life sciences industry the question of going public or private could be a struggle. A key driver for the decision to go public is the availability of funding sources and management’s experiences and relationships, says Punit Dhillon, president and CEO of OncoSec Medical Inc.

  9. Can India Achieve cGMP For Vaccines? Does It Matter? 7/31/2013

    Bharat Biotech pledged to sell Rotovac for the rotavirus for $1 a dose to compete with GSK and Merck, if they make it cheaper can they make it safer?

  10. Takeda's Approach To Becoming A Global Player In The Vaccine Market 7/31/2013

    In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?